Article
Biochemical Research Methods
Samantha M. Sarrett, Cindy Rodriguez, Grzegorz Rymarczyk, Meena M. Hosny, Outi Keinaenen, Samantha Delaney, Sarah Thau, Benjamin A. Krantz, Brian M. Zeglis
Summary: Selective bioconjugation of radioimmunoconjugates was achieved by modifying lysine residues using a simple and facile approach, resulting in better-defined and more homogeneous products compared to stochastic modification. These radioimmunoconjugates exhibited excellent in vitro and in vivo performance.
BIOCONJUGATE CHEMISTRY
(2022)
Article
Cell Biology
Ashleigh Hull, Yanrui Li, Dylan Bartholomeusz, William Hsieh, William Tieu, Tara L. Pukala, Alexander H. Staudacher, Eva Bezak
Summary: This study aimed to develop and test diagnostic and therapeutic radioimmunoconjugates for PDAC. Evaluation of the stability and cell binding affinity showed high cellular binding of Lu-177-DOTA-C595 to MUC1-CE positive cell lines, while Cu-64-DOTA-C595 requires further development and optimization.
Review
Medicine, Research & Experimental
Dayana Nasr, Prashanth Ashok Kumar, Maroun Bou Zerdan, Ghanshyam Ghelani, Dibyendu Dutta, Stephen Graziano, Seah H. Lim
Summary: Immunotherapy has a long history as a treatment option for cancer, and recent advances have made it a realistic therapeutic option for patients with relapsed/refractory malignancies, although most successes so far have been in patients with hematologic malignancies.
Article
Radiology, Nuclear Medicine & Medical Imaging
Samantha Delaney, Abel Nagy, Amelie Eriksson Karlstrom, Brian M. Zeglis
Summary: This study successfully leveraged photoaffinity chemistry and an Fc-binding variant of the Z domain to create a novel site-specific strategy for the synthesis of radioimmunoconjugates. The resulting radioimmunoconjugate exhibited high specific activity, stability, and immunoreactivity, but also showed higher uptake in healthy organs compared to a stochastically modified analog, suggesting the need for optimization before clinical translation.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Chemistry, Medicinal
Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono
Summary: This study developed novel trifunctional chelating agents MDPEI2 and MDPEI4, which enhance the tumor retention of RICs by modifying the radiometabolites with positive charges. The results demonstrate the utility of MDPEI2 in synthesizing RICs with favorable tumor-targeting properties in vivo.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemical Research Methods
Sai Kiran Sharma, Pierre Adumeau, Outi Keinanen, Vikram Sisodiya, Hetal Sarvaiya, Robert Tchelepi, Joshua A. Korsen, Jacob Pourat, Kimberly J. Edwards, Ashwin Ragupathi, Omar Hamdy, Laura R. Saunders, Charles M. Rudin, John T. Poirier, Jason S. Lewis, Brian M. Zeglis
Summary: The study discusses the targeted treatment of DLL3 and introduces an improved radioimmunoconjugate, showing promising in vivo performance through experimental results, suggesting a new potential for clinical application.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Zachary S. Sales, Neelakandha Mani, Aaron T. Herrmann
Summary: This paper describes practical methods for preparing DOTAGA-DBCO and DFO-DBCO from commercially available starting materials. The syntheses of these bifunctional molecules, which possess chelating functionality for binding medically important radiometals and a strained alkyne suitable for Huisgen cyclization with an azide, represent an important step towards improved radioimmunoconjugates for imaging and therapeutic applications.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
Review
Chemistry, Multidisciplinary
Alice Johnson, Joshua Northcote-Smith, Kogularamanan Suntharalingam
Summary: Cancer remains a leading cause of death globally, and despite breakthroughs in clinical therapies using platinum and arsenic compounds, metal complexes have been relatively overlooked in industrial anticancer drug discovery programs. However, the chemical diversity and versatility of metal complexes offer an opportunity to develop novel metallopharmaceuticals that can overcome shortcomings in current cancer treatments. Scientists are currently exploring new ideas and developments to uncover the next generation of anticancer metallopharmaceuticals with clinically relevant efficacies.
TRENDS IN CHEMISTRY
(2021)
Review
Oncology
Liqin Wang, Lina Lankhorst, Rene Bernards
Summary: This review discusses how senescence can be induced in cancer cells and how the distinctive features of senescent cancer cells can be exploited for selective eradication. It also explores activation of the host immune system as an attractive way to clear senescent cancer cells, and the potential benefits of a sequential treatment approach with pro-senescence therapy followed by senolytic therapy.
NATURE REVIEWS CANCER
(2022)
Article
Oncology
Ian L. Linde, Tyler R. Prestwood, Jingtao Qiu, Genay Pilarowski, Miles H. Linde, Xiangyue Zhang, Lei Shen, Nathan E. Reticker-Flynn, David Kung-Chun Chiu, Lauren Y. Sheu, Simon Van Deursen, Lorna L. Tolentino, Wen-Chao Song, Edgar G. Engleman
Summary: Although neutrophils are often used by cancers to promote immunosuppression, tumor growth, and metastasis, this study shows that neutrophils can be harnessed to induce eradication of tumors and reduce metastatic seeding. The combination of tumor necrosis factor, CD40 agonist, and tumor-binding antibody activates human neutrophils in vitro, leading to their lysis of human tumor cells. Mechanistically, this therapy mobilizes neutrophils to infiltrate tumors and activate complement, resulting in the production of leukotriene B4 and subsequent oxidative damage and T cell-independent clearance of multiple tumor types. These findings highlight the potential of using neutrophils as anti-tumor immune mediators.
Review
Chemistry, Multidisciplinary
Amy G. Robertson, Louis M. Rendina
Summary: According to the World Health Organization, the number of new cancer cases and deaths is expected to rise in the next decade, calling for the development of new and effective cancer treatments and diagnostic tools. Theranostics, particularly those utilizing materials like gadolinium, are showing promise in personalized management of oncology patients, representing a new direction in cancer research.
CHEMICAL SOCIETY REVIEWS
(2021)
Review
Biochemistry & Molecular Biology
Philipp Wolf
Summary: Despite improvements in diagnosis and treatment of prostate cancer, there is still an urgent need for new treatment options for advanced stages of the disease. Targeted toxins, which have been developed against prostate cancer, face challenges such as immunogenicity, low target antigen binding, and intracellular degradation. Promising approaches are being developed to potentially overcome these challenges and lead to the clinical use of targeted toxins as therapeutic alternatives for advanced prostate cancer in the future.
Review
Oncology
Michael J. Duffy, Naoise C. Synnott, Shane O'Grady, John Crown
Summary: Dysfunction of the TP53 gene is prevalent in human malignancies, making it an attractive target for new anticancer drugs. Two strategies, reactivating mutant p53 and inhibiting the interaction between wild-type p53 and MDM2/MDM4, are being explored in clinical trials. The development of compounds targeting these strategies has the potential to revolutionize cancer treatment.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Luca Ambrosio, Maria Grazia Raucci, Gianluca Vadala, Luigi Ambrosio, Rocco Papalia, Vincenzo Denaro
Summary: Bone cancer is a challenging disease with currently limited curative treatments. The burden of adverse events and subsequent disability is a major concern, highlighting the need for innovative biomaterials to selectively inhibit cancer progression while preserving healthy bone properties.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Oncology
Ramona Rudalska, Lars Zender, Daniel Dauch
Summary: Metabolic alterations are common in solid tumors, but therapeutic approaches are hindered by the complexity and adaptability of metabolic networks. A recent study demonstrated that targeting the liver X receptor alpha (LXRα) and inhibiting a Raf-1-SCD1 protein complex can induce lethal lipotoxicity in tumor cells, offering a promising treatment avenue for liver carcinomas.
BRITISH JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jean-Baptiste Alberge, Francoise Kraeber-Bodere, Bastien Jamet, Cyrille Touzeau, Helene Caillon, Soraya Wuilleme, Marie-Christine Bene, Tobias Kampfenkel, Pieter Sonneveld, Mark van Duin, Herve Avet-Loiseau, Jill Corre, Florence Magrangeas, Thomas Carlier, Caroline Bodet-Milin, Michel Cherel, Philippe Moreau, Stephane Minvielle, Clement Bailly
Summary: The International Myeloma Working Group has fully incorporated F-18-FDG PET into the diagnosis and response evaluation of multiple myeloma (MM). This study further explores the association between imaging biomarkers and transcriptomic programs in MM, and identifies the combined prognostic value of PMD and a high-risk IFM15 signature in defining MM patients with a very high risk of progression.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Letter
Dermatology
Katleen Blanchet, Jean Charles Sebille, Cecile Frenard, Philippe Lecerf, Amir Khammari, Thomas Carlier, Caroline Bodet-Milin, Brigitte Dreno
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Hematology
Francoise Kraeber-Bodere, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Denis Caillot, Thierry Facon, Xavier Leleu, Karim Belhadj, Emmanuel Itti, Lionel Karlin, Clement Bailly, Mark-David Levin, Monique C. Minnema, Bastien Jamet, Caroline Bodet-Milin, Bart de Keizer, Marie C. Bene, Herve Avet-Loiseau, Pieter Sonneveld, Lixia Pei, Fabio Rigat, Carla de Boer, Jessica Vermeulen, Tobias Kampfenkel, Jerome Lambert, Philippe Moreau
Review
Medicine, General & Internal
Alexandre Lugat, Clement Bailly, Michel Cherel, Caroline Rousseau, Francoise Kraeber-Bodere, Caroline Bodet-Milin, Mickael Bourgeois
Summary: Radioimmunoconjugates have been widely used in nuclear medicine applications for over 30 years. Recent advances in cancer biology have led to the discovery of new molecular targets specific to certain patient subgroups, allowing for the development of specifically tailored therapeutic approaches. Immuno-positron emission tomography (immuno-PET) is a non-invasive imaging modality that utilizes monoclonal antibodies for in vivo characterization of tumor biomarkers, providing valuable information on tumor targeting. Immuno-PET shows great potential in various nuclear medicine applications, including staging/stratification, theranostic approaches, and predictive/prognostic biomarkers. Finding the right balance between isotope choice and immunologic structure is crucial for the development of radiopharmaceutical drugs for immuno-PET.
FRONTIERS IN MEDICINE
(2022)
Meeting Abstract
Hematology
Pierre Peterlin, Joelle Gaschet, Maxime Jullien, Thierry Guillaume, Alice Garnier, Amandine Le Bourgeois, Michel Cherel, Marie C. Bene, Patrice Chevallier
Article
Biochemistry & Molecular Biology
Olivier Espitia, Jeremy Schanus, Christian Agard, Francoise Kraeber-Bodere, Alexis F. Guedon, Antoine Benichou, Jean-Michel Serfaty, Sandrine Coudol, Matilde Karakachoff, Bastien Jamet
Summary: This study aims to diagnose large vessel vasculitis in giant cell arteritis using [F-18]fluorodeoxyglucose-positron emission tomography/computed tomography ([F-18]FDG-PET/CT) and to define a semi-quantitative threshold for distinguishing GCA aortitis from aortic atheroma or the control.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Urology & Nephrology
Francois Lannes, Michael Baboudjian, Alain Ruffion, Mathieu Rouy, Francesco Giammarile, Thierry Rousseau, Francoise Kraeber-Bodere, Caroline Rousseau, Daniela Rusu, Mathilde Colombie, Isabelle Brenot-Rossi, Dominique Rossi, Nicolas Mottet, Cyrille Bastide
Summary: The aim of this study was to evaluate the diagnostic accuracy of sentinel lymph node biopsy-guided lymph node dissection compared to extended pelvic lymph node dissection in intermediate- or high-risk prostate cancer patients. The results showed that sentinel lymph node biopsy is a very effective and sensitive method for pelvic lymph node staging in patients with intermediate- or high-risk localized prostate cancer.
JOURNAL OF UROLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Francesco Cicone, Giulia Santo, Caroline Bodet-Milin, Giuseppe Lucio Cascini, Francoise Kraeber-Bodere, Caroline Stokke, Arne Kolstad
Summary: Systemic radioimmunotherapy (RIT) is considered the most effective and least toxic treatment for non-Hodgkin lymphoma (NHL). Despite a decrease in the number of patients referred for RIT in western countries, RIT has continued to evolve with the identification of new therapeutic targets, production of new vector molecules, and availability of innovative radionuclides.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Oncology
Alexandre Lugat, Eric Frampas, Yann Touchefeu, Eric Mirallie, Maelle Le Bras, Helene Senellart, Aurore Rauscher, Vincent Fleury, Loic Campion, Vincent Rohmer, Olivier-Francois Couturier, Rachida Lebtahi, Francois Rouzet, Philippe Ruszniewski, Francoise Kraeber-Bodere, Mickael Bourgeois, Catherine Ansquer
Summary: In this multicentric study, Ga-68-DOTANOC PET/CT showed higher sensitivity compared to conventional imaging techniques in evaluating the spread of neuroendocrine tumors. It had a significant impact on therapeutic management for almost half of the patients with grade 1-2 gastroenteropancreatic neuroendocrine tumors.
Article
Oncology
Fabienne Desmots, Delphine Rossille, Mikael Roussel, Celine Pangault, Laetitia Louarn, Mylene De Saint Jore, Steven Le Gouill, Krimo Bouabdallah, Vincent Delwail, Remy Gressin, Jerome Cornillon, Gandhi Damaj, Herve Maisonneuve, Diane Damotte, Francoise Kraeber-Bodere, Thierry Lamy, Marie-Cecile Parrens, Noel Milpied, Thierry Fest
Summary: The study aimed to investigate the relationship between the intensity of initial treatment and the baseline cell-free DNA (cfDNA) levels of DLBCL patients, and their impact on long-term survival. The results showed that a high cfDNA concentration at diagnosis was associated with poor clinical prognostic factors and independently predicted worse overall survival. High-cfDNA R-CHOP patients had worse overall survival compared to high-cfDNA R-HDT patients, but salvage therapy and transplantation improved survival in patients with high cfDNA levels.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Bastien Jamet, Caroline Bodet-Milin, Philippe Moreau, Francoise Kraeber-Bodere, Cyrille Touzeau
Summary: T-cell-redirecting bispecific antibodies are now the standard of care for triple-class refractory myeloma patients. A 61-year-old woman with relapsed myeloma underwent 2-[F-18]FDG PET/CT imaging to assess the metabolic response to talquetamab, a GPRC5DxCD3 bispecific antibody. At day 28, the patient showed very good partial response based on monoclonal component assessment, but early bone flare-up was observed through 2-[F-18]FDG PET/CT imaging. By day 84, complete response was confirmed through bone marrow aspirate, M-component assessment, and 2-[F-18]FDG PET/CT, supporting the early flare-up hypothesis.
CLINICAL NUCLEAR MEDICINE
(2023)
Review
Hematology
Cristina Nanni, Carsten Kobe, Bettina Baessler, Christian Baues, Ronald Boellaard, Peter Borchmann, Andreas Buck, Irene Buvat, Bjoern Chapuy, Bruce D. Cheson, Robert Chrzan, Ann-Segolene Cottereau, Ulrich Duhrsen, Live Eikenes, Martin Hutchings, Wojciech Jurczak, Francoise Kraeber-Bodere, Egesta Lopci, Stefano Luminari, Steven MacLennan, N. George Mikhaeel, Marcel Nijland, Paula Rodriguez-Otero, Giorgio Treglia, Nadia Withofs, Elena Zamagni, Pier Luigi Zinzani, Josee M. Zijlstra, Ken Hermaann, Jolanta Kunikowska
Summary: Given the lack of high-certainty evidence and differences in opinion on the use of nuclear medicine for hematological malignancies, a consensus process involving key experts was conducted to provide interim guidance. A three-stage consensus process was used, including a literature review, statement generation, and panel scoring. After two rounds of voting, consensus was reached on most statements, with further studies needed for multiple myeloma and the introduction of new technologies.
LANCET HAEMATOLOGY
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Bastien Jamet, Caroline Bodet-Milin, Philippe Moreau, Cyrille Touzeau, Francoise Kraeber-Bodere
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Valentina Ambrosini, Sofia Carrilho Vaz, Niloefar Ahmadi Bidakhvidi, Marion Chanchou, Matthijs C. F. Cysouw, Francesca Serani, Conrad-Amadeus Voltin, Francoise Kraeber-Bodere, Christophe M. Deroose, Lioe-Fee De Geus-Oei, Matthias Eiber, Gopinath Gnanasegaran, Martin Gotthardt, Carsten Kobe, Mark W. Konijnenberg, Cristina Nanni, Daniela E. Oprea Lager, Kambiz Rahbar, David Taieb, Felix M. Mottaghy, Karolien Goffin, Ken Herrmann
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bastien Jamet, Thomas Carlier, Clement Bailly, Caroline Bodet-Milin, Aurelien Monnet, Eric Frampas, Cyrille Touzeau, Philippe Moreau, Francoise Kraeber-Bodere
Summary: This study aimed to explore the diagnostic performance and clinical value of WB-2-[F-18]FDG-PET/MRI imaging in newly diagnosed multiple myeloma (NDMM). In the study of 52 patients, MRI and PET showed similar effectiveness in detecting FL and diffuse BMI in the symptomatic MM group, but MRI had better diagnostic performance for FL in the SMM group. Overall, WB-2-[F-18]FDG-PET/MRI could represent the next-generation imaging modality for MM.
EUROPEAN RADIOLOGY
(2023)